Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05978713 · ClinicalTrials.gov registry record · Phase 1
A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT05978713 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 11 participants.
The verdict
NCT05978713, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The main purpose of this study was to look if the study drug, tirzepatide, gets into the breastmilk and, if yes, how long it takes the body to get rid of it from the breastmilk. The study drug was given as a single injection under the skin in healthy lactating females. For each participant, the total duration of the study was approximately 8 weeks, including screening.
Interventions
- DRUG Tirzepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2023-07-31 |
| Est. Completion | 2024-03-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05978713
The ClinicalTrials.gov registry entry for NCT05978713 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tirzepatide is the first listed.
NCT05978713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05978713 about?
NCT05978713 is a clinical study titled "A Study of Tirzepatide (LY3298176) in Healthy Lactating Females". The main purpose of this study was to look if the study drug, tirzepatide, gets into the breastmilk and, if yes, how long it takes the body to get rid of it from the breastmilk. The study drug was given as a single injection under the skin in healthy lactating females. For each participant, the tota...
What is the current status of trial NCT05978713?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2023-07-31. Estimated completion is 2024-03-12.
What interventions are being tested in trial NCT05978713?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT05978713?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.